Anxiety and depression in COVID-19: treatment options

• Main Author: V. E. Medvedev
• Format: Article
• Language: Russian
• Published: IMA-PRESS LLC 2021-04-01
• Series: Nevrologiâ, Nejropsihiatriâ, Psihosomatika
• Subjects: pandemic; covid-19; anxiety/depressive disorders; treatment; antidepressants; fluvoxamine; fevarin
• Online Access: https://nnp.ima-press.net/nnp/article/view/1549

During the examination of post-COVID patients, a direct and indirect negative effect of COVID-19 on the nervous system is found. Among the mediated subjectively significant stress factors of the pandemic, a potential long-term threat to life,  prolonged quarantine measures with selfisolation, lack of stable  immunity, restriction of access to medical services, etc. are of  particular importance.An increased frequency of depression (up to 53.5%), anxiety (up  to 50.9%), and mixed anxiety/depressive disorders were  reported during the pandemic.Psychopharmacotherapy in patients with COVID-19 should include drugs not only with minimally expressed undesirable effects and adverse drug interactions but also with the presence of additional therapeutic procognitive and somatotropic properties, similar to those identified in the antidepressant fluvoxamine.